Literature DB >> 18828773

Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation.

M Stern1, R Brand, T de Witte, A Sureda, V Rocha, J Passweg, H Baldomero, D Niederwieser, A Gratwohl.   

Abstract

H-Y encoded gene products were the first to be recognized as clinically relevant minor histocompatibility antigens. Compared to other gender combinations, female donor/male recipient (FDMR) transplants are associated with increased graft-versus-host disease (GvHD), increased transplant-related mortality (TRM) and reduced risk of relapse. Still, their relative impact on transplant outcome remains controversial. We analyzed donor/recipient sex combination in 53,988 patients treated with allogeneic hematopoietic stem cell transplantation (HSCT) between 1980 and 2005. We found a strong increase in chronic GvHD and late TRM and decreased survival in FDMR transplants irrespective of underlying disease. Conversely, FDMR patients had lower relapse rates. The negative effect on survival decreased with advancing disease stage as relapse protection became more important. Effects of H-Y alloreactivity were most pronounced in patients transplanted from HLA-matched donors and in those receiving transplants from an adult donor. Adjustment for acute and chronic GvHD only partially corrected the effects of H-Y alloreactivity. Analysis of the FDMR proportion over time indicated that the frequency of this gender combination has declined in unrelated transplants over the last 10 years. These data define the role of H-Y mismatching in allogeneic HSCT and support the current practice of avoiding female donors for male patients, if possible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18828773     DOI: 10.1111/j.1600-6143.2008.02374.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  26 in total

1.  Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.

Authors:  P R Geethakumari; B Leiby; R Nair; S O Alpdogan; M Carabasi; J Filicko-O'Hara; S Gaballa; M Kasner; T Klumpp; U Martinez-Outschoorn; N Palmisiano; J L Wagner; P Porcu; N Flomenberg; D Grosso
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

Review 2.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 3.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

4.  Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.

Authors:  Wei Wang; Hu Huang; Michael Halagan; Cynthia Vierra-Green; Michael Heuer; Jason E Brelsford; Michael Haagenson; Richard H Scheuermann; Amalio Telenti; William Biggs; Nathaniel M Pearson; Julia Udell; Stephen Spellman; Martin Maiers; Caleb J Kennedy
Journal:  Blood Adv       Date:  2018-10-09

5.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

Review 6.  Clinical impact of H-Y alloimmunity.

Authors:  Rakesh Popli; Bita Sahaf; Hideki Nakasone; Joyce Yeuk Yu Lee; David B Miklos
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

7.  NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Authors:  Jeffrey S Miller; Edus H Warren; Marcel R M van den Brink; Jerome Ritz; Warren D Shlomchik; William J Murphy; A John Barrett; Hans Jochem Kolb; Sergio Giralt; Michael R Bishop; Bruce R Blazar; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-10       Impact factor: 5.742

8.  Donor parity no longer a barrier for female-to-male hematopoietic stem cell transplantation.

Authors:  Astrid G S van Halteren; Miranda P Dierselhuis; Tanja Netelenbos; Mirjam Fechter
Journal:  Chimerism       Date:  2014

9.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

10.  Sex matters, but to what clinical avail?

Authors:  Jennifer C Matthews; Keith D Aaronson
Journal:  Circ Heart Fail       Date:  2009-09       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.